ACHE and early-onset autosomal dominant Alzheimer disease: Current drugs targeting AChE, e.g., to treat symptoms of Alzheimer's disease, are associated with adverse effects, and/or low efficacy [14], warranting searches for new chemical skeletons that could have different pharmacodynamic and pharmacokinetic profiles.